AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours
AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours
MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast cancer
Blood first assay screening in patients with ALK positive NSCLC
Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer
CUPISCO: Identifying carcinoma of unknown primary patients according to ESMO guidelines
CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first-line treatment in advanced hepatocellular carcinoma
INVICTUS: Assessing the safety and efficacy of ripretinib in patients with advanced gastrointestinal stromal tumours
Holistic management of patients with ALK-positive NSCLC
Precision medicine in ALK-positive NSCLC: Results from the BFAST trial
Prostate cancer updates: Advances in precision medicine and PARP inhibitors
Health-related quality of life for patients with metastatic pancreatic cancer: Updates from ESMO 2019
Key developments in pancreatic cancer from ESMO 2019